Table 1: Baseline characteristics Total number of people approved for LA-I Median number per site (IQR) N = 327 21 (19-45) Age (yrs) Median (IQR) <50 50-<60 ≥60 327 (100%) 46 (38-54) 196 (59.4) 95 (29.05) 36 (11.01) Race and Ethnicity White Black or Black British Asian or Asian British Mixed Other Ethnic Groups Not recorded 327 (100%) 155 (47.40) 115 (35.16) 28 (8.56) 8 (2.44) 15 (4.58) 6 (1.83) Gender Cis-men Cis-women Non-binary people Trans-women Trans-men 327 (100%) 244 (74.62) 81 (24.77) 0 (0.00) 2 (0.61) 0 (0.00) Sexuality Homosexual Heterosexual Bisexual Other 324 (99.08%) 194 (59.88) 120 (37.04) 9 (2.78) 1 (0.31) ART regimen prior to switch 3-drug regimen Backbone TDF-based TAF-based ABC-based 3 Agent 1 generation INSTI 2 generation INSTI Non-RPV NNRTI RPV 327 (100%) 276 (84.40) 115 (41.67) 95 (34.42) 66 (23.91) 50 (18.12) 94 (34.06) 54 (19.57) 42 (15.22) EACS2023: 370 UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) K. Ring , L. Okonta , M. Shongwe , M. Smuk , E. Hurn , G. White , W. Barchi , B. Halai , A. Ali , S. Darko , D. Chilton , F. Clark , B. Ali , S. Ayres , N.E. Mackie , B. Thornton , A. Umaipalan , J. Akodu , F. Ferro , T. Barber , G. Quinn , J. Arumainayagam , N. Naous , S. Leung , M. Boffito , B. Ruth , L. Waters , C. Orkin Barts Health NHS Trust, Ambrose King Centre, London, United Kingdom, Queen Mary University of London, SHARE Collaborative, Centre for Immunobiology, Blizard Institute, London, United Kingdom, Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom, Cardiff and Vale University Health Board, Cardiff, United Kingdom, Imperial College Healthcare NHS Trust, London, United Kingdom, Barking, Havering and Redbridge University Hospitals NHS Trust, London, United Kingdom, Royal Free London NHS Foundation Trust, London, United Kingdom, Walsall Healthcare NHS Trust, Walsall, United Kingdom, Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom, Central and North West London NHS Foundation Trust, London, United Kingdom General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Since NHS approval in 2021/22, UK HIV clinics have implemented long-acting injectable (LA-I) cabotegravir and rilpivirine (CAB/RPV) therapy. The impact on NHS HIV services has not been evaluated. This ongoing service evaluation will assess delivery of LA-I with CAB/RPV at 9 NHS clinics. Method: We collected data on pre-defined spreadsheets based on electronic patient records in adults approved for LA-I between 02/2022-05/2023. We describe patient characteristics, reasons for referral, discontinuations and clinic processes (assessment criteria for suitability, time from approval to 1 injection, appointment duration, adherence to 7-day window, recall systems). Results: 327 people were approved for LA-I. The median age was 46 (38-54), 47% (155/327) were White, 24.7% (81/327) were women, and 62.5% (202/327) were gay/bisexual men (Table 1). 80% switched due to inconvenience of oral medication (Figure 1). Suitability: 93.8% received LA-I according to EMEA licensing criteria, 71.9% met BHIVA guidance. 5 people had 2 predictors of virological failure. 13 people discontinued LAI (Figure 2). Median time on CAB/RPV was 140 days (IQR 57-223). 86% received an oral lead-in. 98.8% (847/857) of injections were received within the 7-day window. Process: screening tool criteria differed between clinics (Table 2). Appointment durations ranged from 30-60 minutes and injections were provided by senior nurses. Median time from approval to first injection was 43 days (IQR 18-101.5). HIV viral load testing was performed according to BHIVA guidelines for 93.8% (798/850) of injections. 1,2 1 1 2 3 3 3 3 3 3 3 4 4 5 5 6 6 7 7 7 8 8 9 9 9 9 10 2,1 1 2 3 4 5 6 7 8 9 10 st rd st nd
RkJQdWJsaXNoZXIy Mzc2ODc=